ESMO

• 

ESMO Virtual 2020: Impact of immunotherapy on quality of life

By Sharon Kell|2020-10-08T08:11:27+00:008 Oct 2020|Uncategorized|

In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates [...]

Read More

Comments Off on ESMO Virtual 2020: Impact of immunotherapy on quality of life

• 

Burnout among cancer professionals during COVID-19

By Sharon Kell|2020-09-29T07:48:31+00:0029 Sep 2020|Uncategorized|

Two online surveys presented at the European Society of Medical [...]

Read More

Comments Off on Burnout among cancer professionals during COVID-19

• 

ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

By Sharon Kell|2020-09-22T08:53:22+00:0022 Sep 2020|Uncategorized|

In a paper presented at this year’s European Society of [...]

Read More

Comments Off on ESMO Virtual 2020: Circulating tumour DNA in metastatic kidney cancer patients

• 

ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

By Sharon Kell|2020-09-22T08:31:57+00:0022 Sep 2020|Uncategorized|

Yesterday, findings from the phase 2 biomarker trial, BIONIKK, were [...]

Read More

Comments Off on ESMO Virtual 2020: Biomarker-guided therapy in metastatic kidney cancer

• 

ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

By Sharon Kell|2020-09-21T09:41:33+00:0021 Sep 2020|Uncategorized|

At the European Society of Medical Oncology (ESMO) Virtual Congress [...]

Read More

Comments Off on ESMO Virtual 2020: HIF-2a MK-6482 in Von Hippel-Lindau Disease and kidney cancer

• 

ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

By Sharon Kell|2020-09-21T09:10:13+00:0021 Sep 2020|Uncategorized|

Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]

Read More

Comments Off on ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer

• 

ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

By Sharon Kell|2020-09-21T08:35:09+00:0021 Sep 2020|Uncategorized|

At the European Society of Medical Oncology (ESMO) Virtual Congress [...]

Read More

Comments Off on ESMO Virtual 2020: Nivolumab plus cabozantinib for first-line advanced kidney cancer

• 

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

By Sharon Kell|2020-09-18T08:52:36+00:0018 Sep 2020|Uncategorized|

Over the past 2 years, the use of combination therapies [...]

Read More

Comments Off on ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

• 

Managing cancer patients during the COVID-19 pandemic

By Sharon Kell|2020-08-11T08:43:31+00:0011 Aug 2020|Uncategorized|

The European Society for Medical Oncology (ESMO) has released a [...]

Read More

Comments Off on Managing cancer patients during the COVID-19 pandemic

• 

Artificial intelligence and immuno-oncology

By Sharon Kell|2019-12-19T17:45:46+00:0019 Dec 2019|Cancer news|

The use of artificial intelligence (AI) in clinical practice using [...]

Read More

Comments Off on Artificial intelligence and immuno-oncology